cyrilzakka/clinical-trials huggingface dataset:
Fentanyl Use for Sedation in Esophagogastroduodenoscopy

The purpose of this study is to determine whether conscious sedation with a narcotic and sedative (in combination) is as efficacious as a sedative alone for elective upper endoscopy to achieve optimal patient comfort and ease of procedure.

Upper endoscopy is a valuable procedure that involves a camera advanced from the mouth into the intestines. It is a routine test and considered very safe. However, patients can experience discomfort from air insufflation in the stomach and unpleasantness due to gagging during the procedure. Conscious sedation with medications like sedatives and narcotics are used to improve patient satisfaction and enhance physician ability to perform an optimal examination. The choice of drugs used for sedation in upper endoscopy varies by endoscopist and the goal is always to use the lowest dose possible to achieve the best examination. Combination therapy (with a sedative \& narcotic) may increase the adverse effect profile compared to a sedative alone and not improve the overall experience of the physician or patient. The goal of our study is to assess in randomized, double-blind, placebo controlled study, the effect of using a narcotic (fentanyl) and sedative (midazolam) for sedation compared to a sedative (midazolam) alone.

Eligibility Criteria:
Inclusion Criteria:

* outpatient elective upper endoscopy
* age 18-65
* able to give consent

Exclusion Criteria:

* mental incompetency
* pregnancy
* weight \<55kg or 110 lbs
* emergent procedures,
* known hypersensitivity or allergy to fentanyl or midazolam
* chronic use of benzodiazepines or opioids
* patients known a priori to require therapeutic interventions in conjunction with their EGD
* patients to have major cardiorespiratory comorbidities, obstructive sleep apnea, liver cirrhosis, or renal failure
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.


Eligibility Criteria:
Inclusion Criteria:

* Inoperable non small cell lung cancer
* No weight loss greater than 10% in 3 months prior to enrolling in trial
* Adequate kidney function
* Adequate liver function
* Adequate lung function

Exclusion Criteria:

* Previous surgery to remove lung tumor
* Previous chemotherapy or radiation therapy or lung cancer
* Inability to take vitamin supplementation
* Heart attack within past 6 months
* Active infection
Effects of Therapeutic Exercises in Elderly Women With Knee Osteoarthritis

Knee Osteoarthritis is a degenerative disease associated with muscle weakness, arthralgia, rigidity and postural instability. Therapeutic exercise can reduce pain and improve muscle strength and postural balance, however benefits from association with pompage is not known. This study aims to evaluate the effects of therapeutic exercise on pain, muscle strength and postural balance in elderly women with knee osteoarthritis. Methodology: Almost randomized controlled trial, in which were included elderly between 60 and 80 years diagnosed with knee osteoarthritis, randomized into two groups with 11 participants each. Intervention group held strengthening exercises for flexors and knee extensors, balance training, and manual knee pompage for 12 weeks. Control Group received educational lectures. Arthralgia was estimated by pain subscale of the questionnaire Western Ontario McMaster Universities Osteoarthritis Index and (WOMAC); muscle strength was assessed by the isokinetic dynamometer HUMAC® NORM Testing \& Rehabilitation System and the postural balance by the Biodex Balance SD postural stability protocol (Biodex Medical Systems, Inc. New York, USA). The Student t test was used for statistical analysis.


Eligibility Criteria:
Inclusion Criteria:

* Female
* Aged between 60 and 80 years
* Diagnosed with knee's osteoarthritis according to clinical and radiographic criteria of the American College of Rheumatology.

Exclusion Criteria:

* Cardiovascular and/or unstable respiratory diseases
* Knee or hip arthroplasty; in the last 6 months: surgery on lower limbs, intraarticular corticosteroid injection in the knee, physical therapy
* Associated diseases that contribute to the balance disorders (for example ankylosing spondylitis, rheumatoid arthritis, diabetes mellitus, neurological diseases, Parkinson's disease, cerebral palsy and vestibular).
Clinical Validation of Machine Learning Triage of Chest Radiographs

Artificial intelligence and machine learning have the potential to transform the practice of radiology, but real-world application of machine learning algorithms in clinical settings has been limited. An area in which machine learning could be applied to radiology is through the prioritization of unread studies in a radiologist's worklist. This project proposes a framework for integration and clinical validation of a machine learning algorithm that can accurately distinguish between normal and abnormal chest radiographs. Machine learning triage will be compared with traditional methods of study triage in a prospective controlled clinical trial. The investigators hypothesize that machine learning classification and prioritization of studies will result in quicker interpretation of abnormal studies. This has the potential to reduce time to initiation of appropriate clinical management in patients with critical findings. This project aims to provide a thoughtful and reproducible framework for bringing machine learning into clinical practice, potentially benefiting other areas of radiology and medicine more broadly.


Eligibility Criteria:
Inclusion Criteria:

* Radiologist at Stanford Hospital and Clinics

Exclusion Criteria:

* None
Effect of Hyaluronic Acid ECM on Venous Ulcers

The purpose of this pilot study is to compare the incidence and rate of wound healing in subjects with venous ulcers treated with an extracellular matrix composed of hyaluronic acid plus compression therapy as compared to standard care. The study also intends to follow the subjects for a 16-week period in order to evaluate ulcer recurrence within treatment groups.


Eligibility Criteria:
Inclusion Criteria:

1. Male and female patients 18-85 years of age with chronic venous insufficiency (CVI) and the presence of venous ulceration for longer than 2 months
2. Subject and/or caregiver must be willing and able to tolerate multi-layered compression bandages
3. Study subject must be reliable, responsible and able to visit the clinic weekly for the full 16 week period.

Exclusion Criteria:

1. Ulcers of non-venous etiology
2. Subject has a known sensitivity to hyaluronic acid
3. Presence of wound infection as determined by clinical signs and symptoms
4. Subject has any evidence of peripheral arterial disease (PAD)
5. Subject has received growth factor therapy (e.g., autologous platelet-rich plasma gel, becaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within two weeks of screening date.
6. Pregnancy or lactation at time of treatment.
7. Subject is currently receiving or has received radiation or chemotherapy within 3 months of randomization.
8. Subject currently enrolled or participated within 30 days of baseline in another investigational device, drug or biological trial.
9. History of alcohol or drug abuse.
10. Subject allergic to a broad spectrum of primary \& secondary dressing materials, including occlusive dressings and the adhesives on such dressings.
Clinical Outcomes of Patients with LAL+ in At Least One Eye

The objective of this study is to collect data on bilateral pseudophakic patients implanted with the RxSight Light Adjustable Lens+ (LAL+) in at least one eye

A retrospective-prospective, single-center study will be conducted. Patient charts will be retrospectively reviewed to collect data from the patient's comprehensive preoperative exam. Subjects will attend one stud visit post final LDD light treatment.

Eligibility Criteria:
Inclusion Criteria:

* Adults with bilateral pseudophakia who have been implanted with the LAL+ in at least one eye and who have completed LDD light treatments
* Sign a written Informed Consent Form

Exclusion Criteria:

* Visually significant eye disease
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects

This study is a Phase I, single center, randomized (Parts 1 and 2 only), open-label, 3 part study. Parts 1 and 2 are 2-way crossover, with 1-fixed sequence, 3-period designs to investigate the effect of formulation, food and rabeprazole on the PK of GDC-0853 in healthy male and female (of non-childbearing potential) participants. Part 3 is a fixed-sequence study with 3 treatments to characterize the steady-state PK of the GDC-0853 tablet; the effect of simultaneous administration of a single dose of methotrexate on the steady-state kinetics of GDC-0853; and the effect of dosing GDC-0853 to steady-state on the single dose PK of methotrexate in healthy male participants.


Eligibility Criteria:
Inclusion Criteria:

* Within body mass index range of 18.0 to 31.0 kilograms per square meter (kg/m\^2), inclusive
* For women who are not postmenopausal (greater than or equal to \[\>/=\] 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): these participants will be excluded
* For men: agreement to use a condom plus an additional contraceptive method with their partner during the treatment period and for at least 93 days after the last dose of study drug and agreement to refrain from donating sperm during this same period

Exclusion Criteria:

* Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (as determined by the investigator)
* History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator
* Participants previously enrolled in this study or participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 90 days prior to Period 1 Check-in (Day -1)
* History of malignancy, except for completely excised basal cell carcinoma or squamous cell carcinoma of the skin or cervical carcinoma in situ
* Female participant is pregnant, lactating or breastfeeding
* Current treatment with medications that are well known to prolong the QT interval
* Failure to satisfy the investigator of fitness to participate for any other reason
The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease

Some studies suggest that statin medications may be effective against Alzheimer's disease. However, this has not been proven. The purpose of this study is to evaluate the efficacy of pitavastatin in patients with mild to moderate Alzheimer's disease and hypercholesterolemia.

The PIT-ROAD study will include 50 patients who have taken donepezil more than 3 months stably. This study will see how the use of a particular statin medication, pitavastatin, affects ADAS-Jcog score etc. and cholesterol.

Participants will be given a full information of the study and written informed consent should be obtained before entering the study. Participants will take part in 5 visits over the course of 12 months. If participants have taken cholesterol lowering drug, they will have wash-out period at least 4weeks. Participants will undergo 8 tests (ADAS-Jcog etc., baseline and month 12 visits), complete a medical history questionnaire (baseline), complete medication side effect review through questionnaire and/or blood sample (all visits). Participants will be randomly assigned to receive either pitavastatin or other cholesterol lowering medication for 12 months.

Eligibility Criteria:
Inclusion Criteria:

* Alzheimer's Disease patients (15 ≤ MMSE total score ≤ 23, CDR "1" or "2")
* Patients with hypercholesterolemia
* Patients who have taken donepezil more than 3 months stably
* Both patients and care-givers must be more than 20 years old

Exclusion Criteria:

* Women with pregnancy or breast-feeding
* Malignant tumor
* Cerebrovascular disorder or myocardial infarction prior to 12 weeks
* Heart failure \[New York Heart Association (NYHA) class III or IV\]
* Hepatic or renal dysfunction
* Severe hypertension
* Hypothyroidism, hereditary muscular disease, history of drug-induced myopathy
* Current involvement in another investigational drug study
* Alcoholism, drug abuse
Hemodynamics During the Soccer Championship 2012

The purpose of this study is to determine in soccer fans whether and to which extend positive or negative emotions during the European soccer Championship affects Central Hemodynamics, Arterial Stiffness, Heartrate and Endothelial Dysfunktion.


Eligibility Criteria:
Inclusion Criteria:

Best fit:

* cardiomyopathy "severe myocardial disease leading to heart failure"
* Angina, stable for at least 7 days
* Myocardial infarction during 4 weeks before inclusion, actually stable condition
* Angina, Stable, CCS II-IV

Exclusion Criteria:

* not interested in soccer championship
* age \<18y
* dementia
* atrial tachycardia
* drug/alcohol abuse
* chronic kidney disease, stage 5
* pulmonary/tricuspid valve insufficiency/stenoses
* non compliant
Efficacy of Modified Constraint-induced Movement Therapy in Children With Brain Damage

This research centers on the comparison of the immediate efficacy (right after therapy) and the maintained efficacy (3 months and 6 months) between "Modified Constraint-Induced Movement Therapy" (mCIMT) group and control group at different age.

"Modified Constraint-Induced Movement Therapy" is one of the most recent treatments for children with Brain damage.

This well-designed and follow-up RCT study compared home-based CIT with a control intervention (traditional rehabilitation, TR) by combining kinematic analysis and clinical evaluation, which is possible to examine whether functional improvement is accompanied by a change in motor control. We hypothesized that home-based CIT would induce better motor control strategies (shorter RT, MT, lesser MUs, MGA, and PMGA, and larger peak velocity (PV)) for greater functional gains than TR. Furthermore, the beneficial effects would be maintained at 3 and 6 months of follow-up. Findings of this study allow clinicians to understand the underlying motor control changes for functional improvement after home-based CIT.

Eligibility Criteria:
Inclusion Criteria:

1. Development learned-nonuse
2. Age range 4y/o-15y/o
3. Wrist ext 10˚, MP j't ext 10˚ in affected U/E
4. Can fallow up the simple instruction
5. Modified Ashworth Scale ≦2
6. Pediatric Motor Activity Log ≦2.5 (average)

Exclusion Criteria:

1. Related muscle skeleton surgery
2. Selective dorsal rhizotomy
3. Botulinum toxin in 6 months
4. Visual perception impaired
5. Hearing perception impaired
6. Balance ability impaired (in constrained)
Evaluation of the Diagnostic Value of PET (18F-FDG) in Chronic Graft Versus Host Disease (cGVH)

Allogeneic stem cell transplantation was developed to cure many patients with hematological malignancies. It results in the development of graft versus host disease (GVHD) in 30-70% of cases. Chronic GVHD diagnosis currently uses biopsies of affected organs (skin, liver, gastrointestinal tract) and / or the observation of typical clinical signs sufficient for diagnosis. However, the anatomical sites for biopsy including the digestive tract are not clearly identified (high or low biopsy) and may present risks in their realization in particular in patients weakened by blood disease or immunosuppression.

PET-CT with 18F-FDG has already been evaluated in chronic inflammatory diseases such as Crohns disease with good sensitivity and specificity. It interest in the graft against the host was studied in acute forms of digestive and allows lesion mapping and monitoring the effectiveness of treatment.

Among patients with chronic GVHD scleroderma form, PET with 18F-FDG enabled to view musculoskeletal uptakes localized to the affected areas identified with MRI.

The investigators propose a study evaluating the sensitivity and specificity of the examination by PET-CT with 18F-FDG in the diagnosis of chronic GVHD compared to conventional diagnostic tools.

Patients will have PET/CT at day 150+/-15d post-hematopoietic stem cell transplantation (HSCT)

Eligibility Criteria:
Inclusion Criteria:

* adult \>18 years
* Signed informed consent
* subject covered by a social security system
* Absence of contraindication to PET (18F-FDG)
* Allogeneic stem cell transplantation

Exclusion Criteria:

* Adult patient under tutelage.
* Pregnant or lactating women or women of childbearing potential not currently practicing an adequate method of contraception
* Age\<18 years
* Evolutive infectious disease
* glycemia \>10mmol/L
Clinical Diagnosis of Acute Appendicitis with Normal WBCS Count with Role of Inflammatory Markers and Radiology

The aim of this study is to describe the proportion of pa-tients with normal preoperative inflammatorymarkers among patients with histopathologically proven acute appendicitis

2.4.1- Type of the study: prospective clinical trial study 2.4. 2- Study Setting: Assuit university hospital 2.4. 3- Study subjects:

1. Inclusion criteria:

   patients complain of Rt iliac pain with Us positive for acute appendicitis with WBCS normal .
2. Exclusion criteria:

malignant mass cancer appendix mesenteric adentis cecal diverticulum salpingitis c. Sample Size Calculation: 50 cases 2.4.4 -Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, ...): Lab WBCS count CRP level Neutrophil differential count Clinical correlation US findings and MSCT if needed

Eligibility Criteria:
Inclusion

* Male or female patients é clinically diagnosed acute appendicitis with normal WBCS

Exclusion Criteria:

* complicated AA (perforation, peri appendicular abscess or suspicion of a tumor.

  2_inflammatory bowel diseases 3_inability to co-operate and give informed consent 4_diffuse peritonitis 5_Patients with serious comorbid conditions DM \& renal insufficiency, serum creatinine \> 150 μmol/l 6_Pregnant \& lactating patient 7_Patients with advanced malignancies \& pt on immunosuppressive drugs
Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.

The purpose of this study is to determine if patients with pulmonary hypertension and mildly elevated heart pressure known as PCWP will exhibit different patterns on echocardiography and that these patterns will predict treatment response to sildenafil, a drug given for this condition.


Eligibility Criteria:
Inclusion Criteria:

* Patients with New York Heart Association/World Health Organization(NYHA/WHO)functional class II-III
* Patients with mean pulmonary artery pressure \>25 mmHg, pulmonary capillary wedge pressure \>15 mmHg ≤18, and pulmonary vascular resistance \>3 wood units
* Age \>18 and \<80
* Stable on antihypertensives and diuretics\>3 months
* No evidence of active ischemic heart disease
* 6 minute walk distance \>150 meters and \<450 meters

Exclusion Criteria:

* - Left ventricular ejection fraction \<50%
* Patients with significant restrictive lung disease (FVC\<60% predicted) and/or significant obstructive lung disease (FEV1 \<55% predicted) within 1 year of enrollment
* Poorly interpretable grey scale echocardiographic images
* Contraindications to right heart catheterization
* Nitroglycerin therapy
* Moderate-severe aortic and mitral valve abnormality
* Contraindications to submaximal exercise testing
Effect of Touch Screen Tablet on Fine Motor Functions

the objective of this study to asses the effect of touch screen tablet on fine motor functions


Eligibility Criteria:
Inclusion Criteria:

* hemiplegia
* mid spasticity of upper limb
* able to follow instructions

Exclusion Criteria:

* fixed deformities visual or respiratory problem
Training of Patients With Hip Fracture

The primary purpose of this study is to illustrate whether there is a difference in the 6 minutes walking test in patients with hip fractures who have received 6 vs. 12 weeks of physical training after discharge from hospital.


Eligibility Criteria:
Inclusion Criteria:

* patients with hip fractures
* full weightbearing on the affected leg
* patients living in their own home with an independent walking ability score \>=2 according to the New Mobility Score scale
* written consent

Exclusion Criteria:

* institutionalized patients
* more than 2 weeks after discharge from hospital
* non weight bearing on the affected leg
* Dementia
* other conditions/diagnosis that would have an effect on the ability to train eg. neurological diagnosis
Comparison of Prophylactic Acyclovir and Placebo in Prevention of Eczema Herpeticum in Pediatric Burns

Introduction: Early detection is important in treating patients with Eczema Herpeticum (EH), which may arise in paediatric burn patients. As soon as a clinical diagnosis is confirmed, antiviral medications should be started to ensure an early resolution of the disease. Several studies have indicated that acyclovir is the best treatment for EH lesions in the majority of individuals.

Objective: Compare efficacy of the prophylactic acyclovir and placebo in preventing eczema Herpeticum in paediatric burn patients

Materials and Methods Study design: Randomised control trial. Setting: Pediatric burn unit Mayo hospital Lahore Duration: 1st October 2019 to 30th September 2020. Data collection procedure: All the patients were managed with intravenous fluids, antibiotics, antipyretics and hydrocolloid dressing as per ward routine management protocol along with prophylactic acyclovir and placebo. On the zero day of admission, after parents provided informed consent, patients were randomly assigned to one of two groups using a computer-generated table. Group A patients were given intra venous acyclovir divided into three doses for 7 to 14 days during their stay. Group B patients were given 15% intravenous Hypertonic sodium chloride divided into three doses as placebo for 7 to 14 days, so that parents could be blinded to group allocation. Patients were observed for developing signs of eczema Herpeticum and Tzanck smear was done every 10th day and first follow up at outpatient department after 7days of discharge.

Eligibility Criteria:
* age 1 month to ≤ 13 years .10 to 60 percent total body surface area (TBSA) burn.
* 2nd and 3rd degree burn Exclusion Criteria

  * Patients having previous history of skin disease.
  * Patients having any Comorbidity e.g. Psoriasis, asthma, atopic dermatitis and conjunctivitis.
  * Immunocompromised patients.
  * Patients on steroids or chemotherapy.
  * Patients already having eczema Herpeticum and positive baseline Tzanck smear